Steven Narod

Summary

Affiliation: Women's College Hospital
Country: Canada

Publications

  1. ncbi Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation
    Amy Finch
    Centre for Research in Women s Health, Toronto Sunnybrook Regional Cancer Center, Toronto, Ontario, Canada
    JAMA 296:185-92. 2006
  2. pmc Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers
    Andrea Eisen
    Sunnybrook Regional Cancer Center, Toronto, Ontario, Canada
    J Natl Cancer Inst 100:1361-7. 2008
  3. pmc DNA repair capacity as a possible biomarker of breast cancer risk in female BRCA1 mutation carriers
    J Kotsopoulos
    Centre for Research in Women s Health, Women s College Hospital, 790 Bay Street, Room 750, 7th Floor, Toronto, Ontario, Canada
    Br J Cancer 96:118-25. 2007
  4. doi Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis
    Kelly Metcalfe
    Lawrence S Bloomberg Faculty of Nursing, University of Toronto, Canada
    BMJ 348:g226. 2014
  5. pmc Family history and the risk of gastric cancer
    M Yaghoobi
    Department of Clinical and Metabolic Genetics, Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada
    Br J Cancer 102:237-42. 2010
  6. pmc Cancer risks in first-degree relatives of CHEK2 mutation carriers: effects of mutation type and cancer site in proband
    J Gronwald
    Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland
    Br J Cancer 100:1508-12. 2009
  7. pmc The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers
    J Iqbal
    Women s College Research Institute, Familial Breast Cancer Research, 790 Bay Street, Toronto, Ontario, Canada M5G 1N8
    Br J Cancer 107:2005-9. 2012
  8. pmc Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers
    K Metcalfe
    Lawrence S Bloomberg Faculty of Nursing, University of Toronto, Toronto, Canada
    Br J Cancer 104:1384-92. 2011
  9. pmc An ELISA-based high throughput protein truncation test for inherited breast cancer
    Mark J Lim
    AmberGen, Inc, Watertown, MA 02472, USA
    Breast Cancer Res 12:R78. 2010
  10. ncbi Estimating survival rates after ovarian cancer among women tested for BRCA1 and BRCA2 mutations
    S A Narod
    Women s College Research Institute, University of Toronto, Toronto, Ontario, Canada
    Clin Genet 83:232-7. 2013

Detail Information

Publications140 found, 100 shown here

  1. ncbi Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation
    Amy Finch
    Centre for Research in Women s Health, Toronto Sunnybrook Regional Cancer Center, Toronto, Ontario, Canada
    JAMA 296:185-92. 2006
    ..Women with BRCA1 or BRCA2 mutation are often advised to undergo preventive oophorectomy. The effectiveness of this intervention has not been prospectively evaluated in a large cohort...
  2. pmc Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers
    Andrea Eisen
    Sunnybrook Regional Cancer Center, Toronto, Ontario, Canada
    J Natl Cancer Inst 100:1361-7. 2008
    ....
  3. pmc DNA repair capacity as a possible biomarker of breast cancer risk in female BRCA1 mutation carriers
    J Kotsopoulos
    Centre for Research in Women s Health, Women s College Hospital, 790 Bay Street, Room 750, 7th Floor, Toronto, Ontario, Canada
    Br J Cancer 96:118-25. 2007
    ..These data suggest that these assays are not likely to be useful in the identification of women at a high risk for breast cancer...
  4. doi Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis
    Kelly Metcalfe
    Lawrence S Bloomberg Faculty of Nursing, University of Toronto, Canada
    BMJ 348:g226. 2014
    ..To compare the survival rates of women with BRCA associated breast cancer who did and did not undergo mastectomy of the contralateral breast...
  5. pmc Family history and the risk of gastric cancer
    M Yaghoobi
    Department of Clinical and Metabolic Genetics, Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada
    Br J Cancer 102:237-42. 2010
    ..It is hoped that molecular studies, including genomewide association studies (GWAS), will illuminate the genetic factors underlying this important association...
  6. pmc Cancer risks in first-degree relatives of CHEK2 mutation carriers: effects of mutation type and cancer site in proband
    J Gronwald
    Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland
    Br J Cancer 100:1508-12. 2009
    ..2; 95% CI=2.4-7.8; P=0.0001). These analyses suggest that the risk of cancer in a carrier of a CHEK2 mutation is dependent on the family history of cancer...
  7. pmc The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers
    J Iqbal
    Women s College Research Institute, Familial Breast Cancer Research, 790 Bay Street, Toronto, Ontario, Canada M5G 1N8
    Br J Cancer 107:2005-9. 2012
    ..We estimated the incidence of pancreatic cancer in a cohort of female carriers of BRCA1 and BRCA2 mutation. We also estimated survival rates in pancreatic cancer cases from families with a BRCA mutation...
  8. pmc Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers
    K Metcalfe
    Lawrence S Bloomberg Faculty of Nursing, University of Toronto, Toronto, Canada
    Br J Cancer 104:1384-92. 2011
    ..The objective of this study was to estimate the risk of contralateral breast cancer in BRCA1 and BRCA2 carriers; and measure the extent to which host, family history, and cancer treatment-related factors modify the risk...
  9. pmc An ELISA-based high throughput protein truncation test for inherited breast cancer
    Mark J Lim
    AmberGen, Inc, Watertown, MA 02472, USA
    Breast Cancer Res 12:R78. 2010
    ..Here, we report the next generation HTS-PTT using triple-epitope-tagged proteins and demonstrate, for the first time, its efficacy on clinical genomic DNA samples for BRCA1/2 analysis...
  10. ncbi Estimating survival rates after ovarian cancer among women tested for BRCA1 and BRCA2 mutations
    S A Narod
    Women s College Research Institute, University of Toronto, Toronto, Ontario, Canada
    Clin Genet 83:232-7. 2013
    ..1% to 10.0%. The mortality advantage for tested women was due, in part, to a lower than expected mortality rate of tested women in the period following genetic testing...
  11. doi Should all BRCA1 mutation carriers with stage I breast cancer receive chemotherapy?
    Steven A Narod
    Women s College Research Institute, 790 Bay Street, Room 750, Toronto M5G 1N8, Canada
    Breast Cancer Res Treat 138:273-9. 2013
    ..The difference cannot be explained by other prognostic factors. All women with invasive breast cancer and a BRCA1 mutation should be considered to be candidates for chemotherapy...
  12. pmc Breastfeeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers
    Joanne Kotsopoulos
    Breast Cancer Res 14:R42. 2012
    ..We present an updated analysis of breastfeeding and risk of breast cancer using a large matched sample of BRCA mutation carriers...
  13. doi Tumour characteristics among women with very low-risk breast cancer
    S A Narod
    Women s College Research Institute, University of Toronto, 790 Bay Street, 7th Floor, Toronto, ON, M5G 1N8, Canada
    Breast Cancer Res Treat 134:1241-6. 2012
    ..Small breast cancers that are PR+ and HER2- and that are detectable by mammogram alone have a very low risk of recurrence. A proportion of these may represent examples of overdiagnosis...
  14. doi Breast cancer in young women
    Steven A Narod
    Womens College Research Institute, 790 Bay Street, Toronto, ON M5G 1N8, Canada
    Nat Rev Clin Oncol 9:460-70. 2012
    ..It is hoped that by increasing breast cancer awareness, the proportion of invasive breast cancers that are diagnosed at 2.0 cm or smaller will increase and that this will lead to a reduction in mortality...
  15. pmc Oophorectomy after menopause and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers
    Joanne Kotsopoulos
    Women s College Research Institute, University of Toronto, Toronto, Ontario, Canada
    Cancer Epidemiol Biomarkers Prev 21:1089-96. 2012
    ..To evaluate the effect of the cumulative number of ovulatory cycles and its contributing components on the risk of breast cancer among BRCA mutation carriers...
  16. pmc The R337H mutation in TP53 and breast cancer in Brazil
    Magda Cb Gomes
    Women s College Research Institute, Women s College Hospital, Toronto, ON, Canada
    Hered Cancer Clin Pract 10:3. 2012
    ..abstract:..
  17. pmc Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from Greece
    Chrissovaladis Koumpis
    Women s College Research Institute, Toronto, ON, Canada
    Hered Cancer Clin Pract 9:10. 2011
    ..abstract:..
  18. pmc Identification of a novel truncating PALB2 mutation and analysis of its contribution to early-onset breast cancer in French-Canadian women
    William D Foulkes
    Program in Cancer Genetics, Departments of Oncology and Human Genetics, McGill University, 546 Pine Ave West, Montreal, QC, Canada H2W 1S6
    Breast Cancer Res 9:R83. 2007
    ..We sought to estimate the contribution of PALB2 mutations to the burden of breast cancer in French Canadians from Quebec...
  19. pmc Identification of a novel CHEK2 variant and assessment of its contribution to the risk of breast cancer in French Canadian women
    David J Novak
    Program in Cancer Genetics, Department of Oncology, McGill University, Montreal, QC, H2W 1S6, Canada
    BMC Cancer 8:239. 2008
    ..No founder allele has been specifically identified in the French Canadian population...
  20. pmc The prevalence of BRCA1 mutations among young women with triple-negative breast cancer
    S R Young
    Women s College Research Institute, Department of Public Health, The University of Toronto, Toronto, Canada
    BMC Cancer 9:86. 2009
    ....
  21. pmc Fusion in the ETS gene family and prostate cancer
    S A Narod
    Department of Medicine, Womens College Research Institute, University of Toronto, ON, Canada
    Br J Cancer 99:847-51. 2008
    ..Studies that examine how individual variants and their associated phenotypes affect prostate cancer presentation and progression are required...
  22. ncbi Screening for BRCA1 and BRCA2 mutations in breast cancer patients from Mexico: the public health perspective
    Steven A Narod
    Women s College Research Institute, University of Toronto, Canada
    Salud Publica Mex 51:s191-6. 2009
    ..It is important that a genetic testing service be a multi-disciplinary effort with co-ordinated follow-up...
  23. ncbi Ovarian cancer and HRT in the Million Women Study
    Steven A Narod
    Women s College Research Institute, Toronto, Ontario, Canada M5G 1N8
    Lancet 369:1667-8. 2007
  24. doi Testing for CHEK2 in the cancer genetics clinic: ready for prime time?
    S A Narod
    Womens College Research Institute, 790 Bay, Toronto, Ontario, Canada
    Clin Genet 78:1-7. 2010
    ..These women are good candidates for screening with MRI and for chemoprevention with tamoxifen. It is reasonable to test for this single mutation when women undergo testing for BRCA1 and BRCA2...
  25. doi BRCA mutations in the management of breast cancer: the state of the art
    Steven A Narod
    Womens College Research Institute, 790 Bay Street, Toronto, ON M5G 1N8, Canada
    Nat Rev Clin Oncol 7:702-7. 2010
    ..Mutations in BRCA1 and BRCA2 are presented throughout the world and it is important that the benefits of genetic testing and of targeted therapies be extended to women who live outside of North America and Western Europe...
  26. doi Age of diagnosis, tumor size, and survival after breast cancer: implications for mammographic screening
    Steven A Narod
    Women s College Research Institute, Women s College Hospital, Toronto, ON, M5G 1N8, Canada
    Breast Cancer Res Treat 128:259-66. 2011
    ....
  27. doi Hormone replacement therapy and the risk of breast cancer
    Steven A Narod
    Women s College Research Institute, Toronto, ON M5A 2T3, Canada
    Nat Rev Clin Oncol 8:669-76. 2011
    ..In evaluating a woman who is considering HRT, factors that have been associated with an increased risk include the initiation of hormone use immediately after menopause, a lean body mass and high mammographic breast density...
  28. doi Screening of women at high risk for breast cancer
    Steven A Narod
    Women s College Research Institute, Women s College Hospital and the Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada
    Prev Med 53:127-30. 2011
    ....
  29. doi The impact of contralateral mastectomy on mortality in BRCA1 and BRCA2 mutation carriers with breast cancer
    Steven A Narod
    Womens College Research Institute and Dalla Lana School of Public Health, University of Toronto, 790 Bay Street, Room 750, Toronto, ON M5G 1N8, Canada
    Breast Cancer Res Treat 128:581-3. 2011
    ..4% of women are expected to die of contralateral breast cancer within 5 years, but 6.8% are expected to die at 20 years from diagnosis. These unnecessary deaths can be prevented by bilateral mastectomy...
  30. pmc Rapid progression of prostate cancer in men with a BRCA2 mutation
    S A Narod
    Women s College Research Institute, 790 Bay Street, 7th Floor, Women s College Hospital, University of Toronto, Toronto, Ontario, Canada
    Br J Cancer 99:371-4. 2008
    ..0 years for men with a BRCA1 mutation, and the difference was highly significant (P<0.01). It may be important to develop targeted chemotherapies to treat prostate cancer in men with a BRCA2 mutation...
  31. ncbi Modifiers of risk of hereditary breast cancer
    S A Narod
    The Centre for Research in Women s Health, Women s College Hospital, University of Toronto, Toronto, Canada
    Oncogene 25:5832-6. 2006
    ..Oophorectomy has been associated with reductions in both the risk of breast and ovarian cancer. Knowledge of these risk factors will be useful for managing risk and for developing prevention strategies...
  32. ncbi Breast cancer susceptibility genes
    Jan Lubinski
    Pomeranian Medical University, Department of Genetics and Pathology, International Hereditary Cancer Center, Szczecin, Poland
    J BUON 12:S23-9. 2007
    ..We are presenting it on examples of late-onset breast cancers from Poland, but it seems to be justified to expect that similar results can be achieved from other malignancies...
  33. doi Genetic contribution to all cancers: the first demonstration using the model of breast cancers from Poland stratified by age at diagnosis and tumour pathology
    Jan Lubinski
    Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Polabska 4, 70 115, Szczecin, Poland
    Breast Cancer Res Treat 114:121-6. 2009
    ..Markers associated with majority of groups included: BRCA1, CHEK2, p53, TNRnTT, FGFRnAA, XPD CC/AA and XPD GG. Some markers appeared to be group specific and included polymorphisms in CDKN2A, CYP1B1, M3K nAA, and RS67...
  34. ncbi Use of alternative therapy in postmenopausal breast cancer patients treated with tamoxifen after surgery
    Karen P L Yap
    Department of Surgical Oncology, Princess Margaret Hospital, 610 University Ave, Toronto, Ontario M5G 2M9, Canada
    Breast J 10:481-6. 2004
    ..In conclusion, 27% of patients with early stage breast cancer used alternative therapy. Users were more likely to be younger and to experience shoulder or arm symptoms after breast-conserving surgery with radiation...
  35. ncbi CDKN2A common variant and multi-organ cancer risk--a population-based study
    Tadeusz Debniak
    Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland
    Int J Cancer 118:3180-2. 2006
    ..5; p = 0.5499). These results suggest that A148T variant may be associated with a multi-organ cancer risk in the Polish population...
  36. doi Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy
    Tomasz Byrski
    Department of Genetics andPathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland
    J Clin Oncol 28:375-9. 2010
    ..To estimate the rate of pathologic complete response (pCR) to neoadjuvant chemotherapy in BRCA1 mutation carriers according to chemotherapy regimen...
  37. ncbi The use of preventive measures among healthy women who carry a BRCA1 or BRCA2 mutation
    Kelly A Metcalfe
    Faculty of Nursing, University of Toronto, 50 St George Street, Toronto, Ontario, Canada
    Fam Cancer 4:97-103. 2005
    ....
  38. ncbi A multicenter study of supportive-expressive group therapy for women with BRCA1/BRCA2 mutations
    Mary Jane Esplen
    Behavioral Sciences and Health Research Division, University Health Network, University of Toronto, Toronto, Ontario, Canada
    Cancer 101:2327-40. 2004
    ..The current study developed, standardized, and conducted preliminary testing of a supportive-expressive group therapy intervention designed to address these challenges...
  39. doi Frequency of premature menopause in women who carry a BRCA1 or BRCA2 mutation
    Amy Finch
    Familial Breast Cancer Research, Women s College Research Institute Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada
    Fertil Steril 99:1724-8. 2013
    ..To evaluate the impact of carrying a BRCA1 or BRCA2 mutation on the probability of experiencing premature natural menopause...
  40. ncbi Peritoneal lavage cytology: an assessment of its value during prophylactic oophorectomy
    Terence J Colgan
    Department of Laboratory Medicine and Pathology, Mount Sinai Hospital, Toronto, Canada
    Gynecol Oncol 85:397-403. 2002
    ..This study sought to assess the utility of peritoneal lavage cytology at the time of PO in detecting occult malignancy in this group of patients...
  41. ncbi Significance of multifocality in ductal carcinoma in situ: outcomes of women treated with breast-conserving therapy
    Eileen Rakovitch
    Toronto Sunnybrook Odette Cancer Centre, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, Ontario, Canada
    J Clin Oncol 25:5591-6. 2007
    ..The objective of this study is to evaluate the significance of multifocality and the outcomes of women with multifocal DCIS treated with breast-conserving therapy...
  42. ncbi A high frequency of BRCA2 gene mutations in Polish families with ovarian and stomach cancer
    Anna Jakubowska
    Department of Genetics and Pathology, Pomeranian Academy of Medicine, Szczecin, Poland
    Eur J Hum Genet 11:955-8. 2003
    ..It is expected that the penetrance of BRCA2 mutations for stomach cancer will vary from country to country, reflecting local environmental and lifestyle factors...
  43. ncbi An investigation of the disclosure process and support needs of BRCA1 and BRCA2 carriers
    Jordana Segal
    Department of Psychiatry, Mount Sinai Hospital, Toronto, Ontario, Canada
    Am J Med Genet A 125:267-72. 2004
    ..Both disclosed and non-disclosed carriers demonstrated significant interest in a variety of interventions to support the disclosure process...
  44. ncbi Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study
    John R McLaughlin
    Samuel Lunenfeld Research Institute, Toronto, ON, Canada
    Lancet Oncol 8:26-34. 2007
    ..We aimed to assess the effect of these three risk factors, and of tubal ligation, on the risk of ovarian cancer in women who carry a mutation in the BRCA1 or BRCA2 genes...
  45. pmc Germline HOXB13 p.Gly84Glu mutation and risk of colorectal cancer
    Mohammad R Akbari
    Women s College Research Institute, Women s College Hospital, University of Toronto, Toronto, Canada
    Cancer Epidemiol 37:424-7. 2013
    ..Data has suggested that HOXB13 expression levels are decreased in colorectal cancer (CRC) cell lines indicating this gene may be involved in colorectal tumourigenesis...
  46. ncbi Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers
    Steven A Narod
    The Centre for Research on Women s Health, University of Toronto, 790 Bay Street, Toronto, Ontario M5G 1N8, Canada
    J Natl Cancer Inst 94:1773-9. 2002
    ..We examined whether this association is seen in women at high risk of breast cancer because they carry a mutation in one of two breast cancer susceptibility genes, BRCA1 and BRCA2...
  47. ncbi Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study
    Andrea Eisen
    Toronto Sunnybrook Regional Cancer Center, Toronto, ON, Canada
    J Clin Oncol 23:7491-6. 2005
    ....
  48. doi Toenail selenium status and DNA repair capacity among female BRCA1 mutation carriers
    Joanne Kotsopoulos
    Women s College Research Institute, 790 Bay Street, Toronto, Ontario, Canada
    Cancer Causes Control 21:679-87. 2010
    ..These results provide evidence for a possible protective effect of selenium against BRCA1-associated breast cancers...
  49. pmc Contribution of BRCA1 and BRCA2 mutations to breast and ovarian cancer in Pakistan
    Alexander Liede
    University of Toronto, Sunnybrook and Women s College Health Sciences Centre, Toronto, Ontario, Canada
    Am J Hum Genet 71:595-606. 2002
    ..7; 95% CI 1.5-4.9; P=.0008) and case subjects with ovarian cancer (OR=2.4; 95% CI 1.4-4.2; P=.002). These results suggest that recessively inherited genes may contribute to breast and ovarian cancer risk in Pakistan...
  50. doi BRCA1 haploinsufficiency: consequences for breast cancer
    Leonardo Salmena
    Women s College Research Institute, University of Toronto, Toronto, ON, M5G 1N8, Canada
    Womens Health (Lond Engl) 8:127-9. 2012
    ..They conclude that BRCA1 is a haploinsufficient tumor suppressor gene, which when lost through inheritance, increases a cell's susceptibility to acquire further mutations...
  51. ncbi Factors influencing arm and axillary symptoms after treatment for node negative breast carcinoma
    Karen P L Yap
    Department of Surgical Oncology, Princess Margaret Hospital, University of Toronto, Toronto, Canada
    Cancer 97:1369-75. 2003
    ..The purpose of the current study was to identify the factors that contribute to postoperative arm symptoms following breast conserving surgery in a well-defined cohort of node negative breast carcinoma patients...
  52. ncbi Screening mammography and risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study
    Steven A Narod
    Centre for Research on Women s Health, University of Toronto, Ontario, Canada
    Lancet Oncol 7:402-6. 2006
    ..We aimed to assess whether exposure to ionising radiation through mammography screening was associated with risk of breast cancer in BRCA1 or BRCA2 mutation carriers...
  53. ncbi Age at first birth and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers
    Joanne Kotsopoulos
    Centre for Research in Women s Health, Women s College Hospital, University of Toronto, Room 750, 790 Bay Street, 7th Floor, Toronto, ON M5G 1N8, Canada
    Breast Cancer Res Treat 105:221-8. 2007
    ..Nonetheless, BRCA mutation carriers opting for a prophylactic oophorectomy as a breast and/or ovarian cancer risk-reducing strategy should complete childbearing prior to age 40 when this prevention modality is most effective...
  54. pmc Tamoxifen and the risk of ovarian cancer in BRCA1 mutation carriers
    Danielle Vicus
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Toronto, Ontario, Canada
    Gynecol Oncol 115:135-7. 2009
    ..Our objective is to assess if tamoxifen treatment is associated with an increase in the subsequent risk of ovarian cancer among women with a BRCA1 mutation...
  55. ncbi Hereditary breast and ovarian cancer in Asia: genetic epidemiology of BRCA1 and BRCA2
    Alexander Liede
    Centre for Research in Women s Health, University of Toronto, Toronto, Ontario, Canada
    Hum Mutat 20:413-24. 2002
    ..Studies conducted on the Asian populations described here have expanded our current knowledge of genetic susceptibility and its contribution to breast and ovarian cancer rates in Asian populations...
  56. ncbi Psychosocial functioning in women who have undergone bilateral prophylactic mastectomy
    Kelly A Metcalfe
    Faculty of Nursing, University of Toronto, Toronto, Ontario, Canada
    Psychooncology 13:14-25. 2004
    ....
  57. pmc Changes in body weight and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers
    Joanne Kotsopoulos
    Centre for Research in Women s Health, Women s College Hospital, University of Toronto, Toronto, ON, Canada
    Breast Cancer Res 7:R833-43. 2005
    ..We asked whether there is an association between changes in body weight and the risk of breast cancer in women who carry a mutation in either breast cancer susceptibility gene, BRCA1 or BRCA2...
  58. ncbi Prevention and management of hereditary breast cancer
    Steven A Narod
    Centre for Research in Women s Health, University of Toronto, 790 Bay St, Toronto, Ontario M5G 1N8, Canada
    J Clin Oncol 23:1656-63. 2005
  59. ncbi Modifiers of risk of hereditary breast and ovarian cancer
    Steven A Narod
    Centre for Research on Women s Health, Women s College Hospital, 790 Bay Street, Room 750, University of Toronto, Toronto, Canada M5G 1N8
    Nat Rev Cancer 2:113-23. 2002
    ..Genetic risk can be modified by external factors, but what are these factors, and how might our knowledge of them help us to better define the risks for individual women and to develop strategies for cancer prevention?..
  60. pmc Smoking and the risk of breast cancer in BRCA1 and BRCA2 carriers: an update
    Ophira Ginsburg
    The Campbell Family Institute for Breast Cancer Research at Princess Margaret Hospital, Toronto, ON, Canada
    Breast Cancer Res Treat 114:127-35. 2009
    ..There is a possibility of an increased risk of breast cancer among BRCA1 carriers associated with past smoking. There may be different effects of carcinogens in BRCA mutation carriers, depending upon the timing of exposure...
  61. doi Systematic review of bone health in older women treated with aromatase inhibitors for early-stage breast cancer
    Taryn Becker
    Department of Medicine, University of Toronto, Toronto, Ontario, Canada
    J Am Geriatr Soc 60:1761-7. 2012
    ..To review data from randomized controlled trials (RCTs) that evaluate adverse bone outcomes in older women using aromatase inhibitors (AIs) for early-stage hormone receptor-positive breast cancer...
  62. ncbi What options for treatment of hereditary breast cancer?
    Steven Narod
    Centre for Research on Women s Health, Sunnybrook and Women s College Health Sciences Centre, Toronto, ON M5G 1N8, Canada
    Lancet 359:1451-2. 2002
  63. pmc International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers
    Kelly A Metcalfe
    Lawrence S Bloomberg Faculty of Nursing, University of Toronto, Toronto, ON, Canada
    Int J Cancer 122:2017-22. 2008
    ..Approximately one-half of women at risk for breast cancer rely on screening alone...
  64. doi Polymorphisms in folate metabolizing enzymes and transport proteins and the risk of breast cancer
    Joanne Kotsopoulos
    Women s College Research Institute, Women s College Hospital, University of Toronto, Toronto, Canada
    Breast Cancer Res Treat 112:585-93. 2008
    ..Individual variation in the genes involved in the transport of folate, or its metabolism, may affect risk, or may modify the association between folate and breast cancer risk...
  65. doi Infertility, treatment of infertility, and the risk of breast cancer among women with BRCA1 and BRCA2 mutations: a case-control study
    Joanne Kotsopoulos
    Women s College Research Institute, Women s College Hospital, University of Toronto, Toronto, ON, Canada
    Cancer Causes Control 19:1111-9. 2008
    ..It is important to evaluate whether or not infertility per se or exposure to fertility medications increase the risk of breast cancer in genetically predisposed women...
  66. pmc Polymorphic variation of genes in the fibrinolytic system and the risk of ovarian cancer
    Yaakov Bentov
    Department of Obstetrics and Gynecology, University of Toronto, Toronto, Canada
    PLoS ONE 4:e5918. 2009
    ..These were considered to be candidate genes in the present study...
  67. ncbi The CYP1A2 genotype modifies the association between coffee consumption and breast cancer risk among BRCA1 mutation carriers
    Joanne Kotsopoulos
    Centre for Research in Women s Health, Women s College Hospital, University of Toronto, Canada
    Cancer Epidemiol Biomarkers Prev 16:912-6. 2007
    ..This study suggests that caffeine protects against breast cancer in women with a BRCA1 mutation and illustrates the importance of integrating individual genetic variability when assessing diet-disease associations...
  68. doi Germline RAP80 mutations and susceptibility to breast cancer
    Mohammad Reza Akbari
    Women s College Research Institute, University of Toronto, 790 Bay Street, 7th Floor, Toronto, ON, Canada
    Breast Cancer Res Treat 113:377-81. 2009
    ..A novel RAP80 haplotype or rare missense mutations may be associated with a modest increased risk of breast cancer, but this observation needs to be confirmed by additional studies...
  69. ncbi A BRCA1 mutation is not associated with increased indicators of oxidative stress
    Joanne Kotsopoulos
    Women s College Research Institute, Women s College Hospital, Department of Nutritional Sciences, Faculty of Medicine, University of Toronto, Ontario, Canada
    Clin Breast Cancer 8:506-10. 2008
    ..It is possible that individuals with a BRCA1 mutation might be susceptible to the effects of oxidative stress. The aim of this study was to evaluate whether women with a BRCA1 mutation exhibit increased indicators of oxidative stress...
  70. ncbi Mutations of the MYH gene do not substantially contribute to the risk of breast cancer
    Mario E Beiner
    Women s College Research Institute, Women s College Hospital, 790 Bay Street, 7th Floor, Toronto, ON, Canada M5G 1N8
    Breast Cancer Res Treat 114:575-8. 2009
    ..To explore whether or not there is an association between the presence of either of the germline mutations in the MutY human homologue (MYH) gene (Y165C and G382D) and the risk of breast cancer...
  71. ncbi Satisfaction with breast reconstruction in women with bilateral prophylactic mastectomy: a descriptive study
    Kelly A Metcalfe
    Faculty of Nursing, University of Toronto, Ontario, Canada
    Plast Reconstr Surg 114:360-6. 2004
    ..Correcting overestimation of breast cancer risk in women who have prophylactic mastectomy may improve satisfaction with reconstruction following prophylactic mastectomy...
  72. ncbi BRCA1 and BRCA2: 1994 and beyond
    Steven A Narod
    Centre for Research on Women s Health, Sunnybrook and Womens College Health Sciences Center, 790 Bay Street, Toronto, Ontario M5G 1N8, Canada
    Nat Rev Cancer 4:665-76. 2004
    ..The ability to translate this knowledge into novel treatments, however, remains elusive...
  73. ncbi A low frequency of non-founder BRCA1 mutations in Ashkenazi Jewish breast-ovarian cancer families
    Catherine M Phelan
    Center for Research in Women s Health, Toronto, Ontario, Canada
    Hum Mutat 20:352-7. 2002
    ..Non-founder BRCA1 mutations are rare in Ashkenazi Jewish breast/ovarian cancer families...
  74. ncbi A BRCA1 mutation in Native North American families
    Alexander Liede
    University of Toronto and Sunnybrook and Women s College, Health Sciences Centre, Toronto, Canada
    Hum Mutat 19:460. 2002
    ..The families represent two aboriginal Canadian tribes (Cree and Ojibwe), although a common ancestral origin is likely. This is the first evidence of a BRCA1 mutation specific to aboriginal peoples of North America...
  75. ncbi Cancer incidence in a population of Jewish women at risk of ovarian cancer
    Alexander Liede
    Centre for Research in Women s Health, Sunnybrook and Women s College Health Sciences Centre, Toronto, Ontario, Canada
    J Clin Oncol 20:1570-7. 2002
    ..To evaluate the incidence and clinical characteristics of ovarian and other cancers in a cohort of women at risk of developing ovarian cancer...
  76. ncbi Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers
    Kelly Metcalfe
    Centre for Research on Women s Health, Women s College Hospital, Toronto, Ontario, Canada
    J Clin Oncol 22:2328-35. 2004
    ..To estimate the risk of contralateral breast cancer in BRCA1 and BRCA2 carriers after diagnosis and to determine which factors are predictive of the risk of a second primary breast cancer...
  77. ncbi Age at menarche and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers
    Joanne Kotsopoulos
    Centre for Research in Women s Health, University of Toronto, Women s College Hospital, 790 Bay Street, 7th Floor, Totonto, Ontario M5G 1N8, Canada
    Cancer Causes Control 16:667-74. 2005
    ..46; 95% CI 0.30-0.69). This study implicates early age at menarche as a determinant of breast cancer among women with a BRCA1 mutation...
  78. ncbi Increased rates of chromosome breakage in BRCA1 carriers are normalized by oral selenium supplementation
    Elzbieta Kowalska
    Centre for Research in Women s Health, 790 Bay Street, Toronto, Ontario, Canada, M5G 1N8
    Cancer Epidemiol Biomarkers Prev 14:1302-6. 2005
    ..40 versus 0.39). Oral selenium is a good candidate for chemoprevention in women who carry a mutation in the BRCA1 gene...
  79. ncbi Hormone replacement therapy and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers
    Joanne Kotsopoulos
    Centre for Research in Women s Health, 790 Bay Street, 7th Floor, Women s College Hospital, University of Toronto, Toronto, Ontario, Canada M5G 1N8
    Gynecol Oncol 100:83-8. 2006
    ..This association has not been evaluated in BRCA1 or BRCA2 mutation carriers who face very high lifetime risks of both breast and ovarian cancers...
  80. ncbi The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers
    Kelly A Metcalfe
    Faculty of Nursing, University of Toronto, 50 St George Street, Toronto, ON, Canada, M5S 3H4
    Gynecol Oncol 96:222-6. 2005
    ..To estimate the risk of ovarian cancer after a primary diagnosis of breast cancer among women with a BRCA1 or BRCA2 mutation and to identify host and treatment-related factors that might modify the risk...
  81. doi Screening for pancreatic cancer in a high-risk cohort: an eight-year experience
    Wigdan Al-Sukhni
    Hepatobiliary Pancreatic Surgical Oncology Program, Division of General Surgery, Department of Surgery, University Health Network, University of Toronto, Toronto, Canada
    J Gastrointest Surg 16:771-83. 2012
    ..Pancreatic adenocarcinoma is the fourth leading cause of cancer death...
  82. pmc Uptake of clinical genetic testing for ovarian cancer in Ontario: a population-based study
    Kelly A Metcalfe
    Lawrence S Bloomberg Faculty of Nursing, University of Toronto, Toronto, Ontario, Canada
    Gynecol Oncol 112:68-72. 2009
    ..It is unknown what proportion of women with ovarian cancer receive genetic testing as a result of this recommendation...
  83. ncbi A comparison of bilateral breast cancers in BRCA carriers
    Jeffrey N Weitzel
    The Centre for Research in Women s Health, 790 Bay Street, Toronto, Ontario, Canada M5G 1N8
    Cancer Epidemiol Biomarkers Prev 14:1534-8. 2005
    ..It is generally believed that the two cancers represent independent events. However, the extent of concordance between the first and second tumors with respect to hormone receptor expression and other pathologic features is unknown...
  84. ncbi The N314D polymorphism of galactose-1-phosphate uridyl transferase does not modify the risk of ovarian cancer
    W L Alan Fung
    The Center for Research in Women s Health, University of Toronto, Toronto, Ontario, M5G 1N8 Canada
    Cancer Epidemiol Biomarkers Prev 12:678-80. 2003
    ..We conclude that the GALT N314D allele does not predispose to epithelial ovarian cancer...
  85. ncbi Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination
    Ellen Warner
    Division of Medical Oncology, Department of Medicine, Sunnybrook and Women s College Health Sciences Centre and University of Toronto, Ontario, Canada
    JAMA 292:1317-25. 2004
    ..Magnetic resonance imaging (MRI) and ultrasound may improve the ability to detect breast cancer at an early stage...
  86. ncbi Androgen receptor gene polymorphism and breast cancer susceptibility in The Philippines
    Alexander Liede
    University of Toronto and Sunnybrook Women s College Health Sciences Centre, Toronto, Ontario M5G 1N8, Canada
    Cancer Epidemiol Biomarkers Prev 12:848-52. 2003
    ..These findings support the theory that short trinucleotide repeat genotypes of the AR gene protect against breast cancer...
  87. doi Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women
    Kelly A Metcalfe
    Lawrence S Bloomberg, Faculty of Nursing and Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada
    J Clin Oncol 28:387-91. 2010
    ..To date, population screening in this population has not been suggested. However, this may be rational. Little is known about the appropriateness of testing guidelines for the Jewish population or the level of interest in testing...
  88. ncbi Breast tissue organochlorine levels and metabolic genotypes in relation to breast cancer risk Canada
    David McCready
    Department of Surgery, University Health Network, Toronto, Ontario, Canada
    Cancer Causes Control 15:399-418. 2004
    ..2; 95% CI = 1.1-4.4). However, multiple comparisons were made and generally our data do not support the hypothesis that organochlorines increase the risk of breast cancer among subgroups of women with specific metabolic genotypes...
  89. doi Risk factors for carcinoma of the fallopian tube in women with and without a germline BRCA mutation
    Danielle Vicus
    Women s College Research Institute, 790 Bay Street, Toronto, Ontario, Canada
    Gynecol Oncol 118:155-9. 2010
    ..The purpose of this study was to identify risk factors for fallopian tube cancer in women with and without a BRCA mutation...
  90. ncbi Current understanding of the epidemiology and clinical implications of BRCA1 and BRCA2 mutations for ovarian cancer
    Steven A Narod
    The Centre for Research on Women s Health, Women s College Hospital, University of Toronto, Toronto, Canada
    Curr Opin Obstet Gynecol 14:19-26. 2002
    ..Strategies for prevention of ovarian cancer among carriers include oral contraceptives, tubal ligation and prophylactic oophorectomy...
  91. ncbi Risk factors for non-invasive lesions of the fallopian tube in BRCA mutation carriers
    Danielle Vicus
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Toronto, Ontario, Canada
    Gynecol Oncol 118:295-8. 2010
    ..To identify risk factors for the presence of a non-invasive lesion of the fallopian tube in women with a BRCA1 or BRCA2 mutation...
  92. ncbi Heterozygosity for the BLM(Ash) mutation and cancer risk
    Sean P Cleary
    Centre for Cancer Genetics, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada
    Cancer Res 63:1769-71. 2003
    ....
  93. ncbi Towards a dietary prevention of hereditary breast cancer
    Joanne Kotsopoulos
    Centre for Research in Women s Health, Toronto, Ontario, Canada
    Cancer Causes Control 16:125-38. 2005
    ..The prevention of hereditary breast cancer through diet is an attractive complement to current management strategies and deserves exploration...
  94. ncbi Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers
    Amy Finch
    The Centre for Research in Women s Health, 790 Bay Street, 7th Floor, Toronto, ON, Canada M5G 1N8
    Gynecol Oncol 100:58-64. 2006
    ..To estimate the likelihood of occult cancer diagnosis at prophylactic oophorectomy in BRCA1 and BRCA2 carriers in different age groups and to determine the histopathology of these lesions...
  95. ncbi Method of cooking and risk of breast cancer in the Philippines
    Joanne Kotsopoulos
    Centre for Research in Women s Health, Women s College Hospital, University of Toronto, Ontario, Canada
    Cancer Causes Control 17:341-8. 2006
    ..We conducted a case-control study in Manila to examine the association between methods of cooking and the risk of breast cancer...
  96. ncbi The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study
    Mario E Beiner
    Centre for Research in Women s Health, 790 Bay Street, Toronto, ON, Canada M5G 1N8
    Gynecol Oncol 104:7-10. 2007
    ..To evaluate the risk of endometrial cancer in women who carry a deleterious mutation in the BRCA1 or BRCA2 genes...
  97. ncbi The role of reexcision for positive margins in optimizing local disease control after breast-conserving surgery for cancer
    Dalal Aziz
    Department of Surgery and Biostatistics, Centre for Research in Women s Health, Sunnybrook and Women s College Health Sciences Centre, Toronto, Ontario, Canada
    Breast J 12:331-7. 2006
    ..Reexcision to clear involved margins is an important surgical intervention for both younger and older women...
  98. ncbi Association between CYP3A4 genotype and risk of endometrial cancer following tamoxifen use
    William Chu
    Department of Radiation Oncology, Princess Margaret Hospital University Health Network, Toronto, Ontario, Canada
    Carcinogenesis 28:2139-42. 2007
    ..004). These findings suggest that a subgroup of breast cancer patients who carry the CYP3A4*1B allele and take tamoxifen may be at increased risk of developing endometrial cancer...
  99. ncbi A fluorescent multiplex-DGGE screening test for mutations in the BRCA1 gene
    Graciela Kuperstein
    The Centre for Research in Women s Health, University of Toronto, Toronto, Ontario, Canada
    Genet Test 10:1-7. 2006
    ..This technique may prove to be a useful research tool for the detection of mutations and polymorphisms in the BRCA1 gene and for large-scale epidemiologic studies...